Inorganic Chemistry
Article
1
yield (1.15 g, 2.49 mmol). H NMR (300 MHz, CDCl3) δ (ppm):
0.96 (t, J = 7.5 Hz, 6H), 1.22 (s, 6H), 2.29 (q, J = 7.5 Hz, 4H), 2.30 (t,
J = 2.5 Hz, 1H), 2.51 (s, 6H), 3.78 (dd, J = 2.5 Hz, J = 5.2 Hz, 2H),
6.27 (t, J = 5.2 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz,
2H). 13C NMR (75 MHz, CDCl3) δ (ppm): 11.9, 12.5, 14.6, 17.1,
30.9, 72.1, 79.3, 127.8, 128.9, 130.4, 133.1, 134.0, 138.1, 138.5, 139.7,
154.3, 166.2. 11B NMR (192.5 MHz, CDCl3) δ (ppm): 0.78 (t, J =
33.4 Hz). UV−vis (2-MeTHF) λmax (nm) (ε × 10−3 L mol−1 cm−1):
238 (39), 494 (27), 525 (90). MS (ESI) m/z = 460.39 [M + H]+,
484.34 [M + Na]+. HRMS (ESI) 484.235 59 calcd for C27H30B-
F2N3ONa 484.234 70.
refluxed during 2 h in a Dean−Stark apparatus, and the solvent was
removed in situ. Dry toluene (50 mL) and piperidine (3 mL) were
added, and the mixture was refluxed for another 2 h. After
consumption of approximately a third of the starting material
(monitored by UV−vis), the solvent was evaporated. The resulting
solid was washed with water (3 × 100 mL) and extracted with
dichloromethane. The organic layer was dried over magnesium sulfate,
and the solvent was evaporated to give a blue solid. The crude product
was purified by column chromatography on silica gel (dichloro-
methane/heptane 40:60), followed by a recrystallization in a mixture
of dichloromethane and hexane to give 7 (73.0 mg, 125 μmol) in 5%
1
Compound 3. Compound 2 (100 mg, 0.22 mmol) and p-
anisaldehyde (106 μL, 0.870 mmol) were dissolved in a mixture of
dry toluene (40 mL), p-toluenesulfonic acid (PTSA, 6.0 mg, 0.035
mmol), and piperidine (752 μL, 7.60 mmol). The mixture was refluxed
during 2 h in a Dean−Stark apparatus, and the solvent was removed in
situ. Dry toluene (40 mL) and 750 μL of piperidine were added, and
the mixture was refluxed for another 2 h. After total consumption of
the starting material (monitored by UV−vis), the solvent was
evaporated. The resulting solid was washed with water (3 × 100
mL) and extracted with dichloromethane. The organic layer was dried
over magnesium sulfate, and the solvent was evaporated to give a blue
solid. The crude product was purified by column chromatography on
silica gel (heptane/CH2Cl2 80:20), followed by a recrystallization in a
mixture of dichloromethane and hexane to give a blue solid in 36%
yield. Compound 6 was also obtained as subproduct in 3% yield. H
NMR (300 MHz, CDCl3) δ (ppm): 0.97 (t, J = 7.5 Hz, 3H), 1.12 (t, J
= 7.5 Hz, 3H), 1.25 (s, 3H), 1.27 (s, 3H), 2.29 (q, J = 7.5 Hz, 2H),
2.52 (t, J = 2.4 Hz, 1H), 2.56 (s, 3H), 2.56 (q, J = 7.5 Hz, 2H), 3.97 (s,
3H), 4.71 (d, J = 2.4 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 7.16 (d, J =
16.8 Hz, 1H), 7.41 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.60
(d, J = 16.8 Hz, 1H), 8.16 (d, J = 8.3 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ (ppm): 11.8, 12.1, 13.0, 14.3, 14.7, 17.3, 17.5, 18.5, 52.6,
56.1, 75.9, 78.6, 115.4, 118.6, 128.8, 129.1, 130.5, 130.9, 131.3, 131.6,
133.4, 134.0, 135.1, 138.0, 141.1, 150.0, 155.8, 158.2, 166.8. 11B NMR
(192.5 MHz, CDCl3) δ (ppm): 0.98 (t, J = 33.8 Hz). UV−vis (2-
MeTHF): λmax (nm) (ε × 10−3 L mol−1 cm−1) = 238 (19), 319 (17),
339 (29), 389 (8), 448 (27), 587 (81). MS (ESI): m/z = 603.4 [M +
Na]+. HRMS (ESI) 603.262 33 calcd for C35H35BF2N2O3Na 603.260
71.
1
yield (55.0 mg, 78.8 μmol). H NMR (300 MHz, CDCl3) δ (ppm):
1.14 (t, J = 7.5 Hz, 6H), 1.28 (s, 6H), 2.32 (t, J = 2.5 Hz, 1H), 2.58 (q,
J = 7.5 Hz, 4H), 3.84 (s, 6H), 4.30 (dd, J = 2.5 Hz, J = 5.2 Hz, 2H),
6.36 (t, J = 5.2 Hz, 1H), 6.93 (d, J = 8.7 Hz, 4H), 7.20 (d, J = 16.7 Hz,
2H), 7.43, (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.7 Hz, 4H), 7.65 (d, J =
16.7 Hz, 2H), 7.93 (d, J = 8.3 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ
(ppm): 11.8, 14.1, 18.4, 55.4, 72.2, 79.3, 114.3, 127.8, 128.9, 129.4,
130.3, 132.5, 133.9, 134.1, 135.8, 136.1, 138.3, 140.1, 150.9, 160.3,
166.3. 11B NMR (192.5 MHz, CDCl3) δ (ppm): 1.23 (t, J = 34.2 Hz).
UV−vis (2-MeTHF): λmax (nm) (ε × 10−3 L mol−1 cm−1): 250 (21),
334 (31), 368 (68), 608 (37), 654 (93). MS (ESI): m/z = 720.35 [M
+ Na]+. HRMS (ESI) 720.320 39 calcd for C43H42BF2N3O2Na
720.318 69.
General Procedure for the Huisgen Reaction. 10-(4-
Azidomethylphenyl)-5,15-dimesityl-corrole gallium(III)(pyridine)
(30.0 mg, 37.0 μmol or 60.0 mg, 74.0 μmol for preparation of
compound 8) and BODIPY alkyne (37.0 μmol) were solubilized in 5
mL of THF. CuI (10.5 mg, 55.1 μmol or 21.0 mg, 110 μmol for
preparation of compound 8) and N,N-diisopropylethylamine (DIPEA)
(14.0 μL, 148 μmol) were added. The mixture was stirred under N2 at
RT for 3 h. The crude mixture was evaporated to dryness. Then 20 mL
of water was added. The compound was extracted with dichloro-
methane (3 × 20 mL). The collected organic solution was dried over
MgSO4, and the solvent was removed under reduced pressure. The
product was recrystallized from CH2Cl2−hexane.
Compound 6. BODIPY ester18 (200 mg, 0.46 mmol) and 4-(prop-
2-yn-1-yloxy)benzaldehyde (73.0 mg, 0.460 mmol) were dissolved in a
mixture of dry toluene (20 mL), p-toluenesulfonic acid (PTSA, 50.0
mg, 0.290 mmol), and piperidine (989 μL, 10.0 mmol). The mixture
was refluxed during 2 h in a Dean−Stark apparatus. The solvent was
removed in situ, and 10 mL of dry toluene and 73 mg of 4-(prop-2-yn-
1-yloxy)benzaldehyde were added. The mixture was refluxed for
another 1 h, and solvent was removed. This step was repeated five
times. After total consumption of starting material (monitored by
UV−visible), the solvent was evaporated. The resulting solid was
washed with water (3 × 50 mL) and extracted with dichloromethane.
The organic layer was dried over magnesium sulfate, and the solvent
was evaporated to give a blue solid. The crude product was purified by
column chromatography on silica gel (dichloromethane/heptane
50:50), followed by a recrystallization in a mixture of dichloromethane
and hexane to give 6 (133 mg, 184 μmol) in 40% yield as blue solid.
1H NMR (300 MHz, CDCl3) δ (ppm): 1.13 (t, J = 7.6 Hz, 6H), 1.28
(s, 6H), 2.53 (t, J = 2.4 Hz, 2H), 2,58 (q, J = 7.6 Hz, 4H), 3.97 (s,
3H), 4.73 (d, J = 2.4 Hz, 4H), 7.01 (d, J = 8.8 Hz, 4H), 7.20 (d, J =
16.6 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.8 Hz, 4H), 7.66
(d, J = 16.6 Hz, 2H), 8.20 (d, J = 8.2 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ (ppm): 10.7, 13.0, 17.4, 51.4, 54.9, 74.7, 77.3, 114.2, 117.5,
127.8, 128.1, 129.3, 129.6, 130.1, 131.5, 133.0, 134.6, 137.4, 140.8,
149.8, 151.2, 157.1, 165.6. UV−vis (2-MeTHF): λmax (nm) (ε × 10−3
L mol−1 cm−1) = 255 (21), 332 (31), 366 (63), 428 (11), 604 (36),
654 (85). 11B NMR (192.5 MHz, CDCl3) δ (ppm): 1.20 (t, J = 34.6
Hz). MS (ESI): m/z = 745.30 [M + Na]+. HRMS (ESI) 745.303 08
calcd for C45H41BF2N2O4Na 745.302 73.
Compound 4. The title compound was isolated as a purple
1
microcrystalline solid in 96% yield (45.0 mg, 35.4 μmol). H NMR
(300 MHz, pyridine-d5) δ (ppm): 0.84 (m, 6H, CH3), 1.20 (s, 6H,
CH3), 2.13 (m, 16H, CH2, CH3), 2.62 (s, 6H, CH3), 2.70 (s, 6H,
CH3), 5.25 (d, 2H, J = 5.1 Hz, CH2N), 6.05 (s, 2H, CH2), 7.38 (m,
6H, Hmes, HPh), 7.49 (s, 1H, Htriazole), 7.76 (d, 2H, J = 7.8 Hz, HPh),
8.20 (d, 2H, J = 8.1 Hz, HPh), 8.46 (d, 2H, J = 8.1 Hz, HPh), 8.79 (m,
4H, Hβ), 8.88 (d, 2H, J = 4.5 Hz, Hβ), 9.25 (d, 2H, J = 3.9 Hz, Hβ),
10.07 (m, 1H, NH). UV−vis (2-MeTHF): λmax (nm) (ε × 10−3
L
mol−1 cm−1) = 419 (150), 525 (80), 567 (13), 600 (21). MS
(MALDI-TOF) m/z = 1173.46 [M-pyridine-F]+, 1173.47 calcd for
C71H66BFGaN10O. HR-MS (ESI) m/z = 1192.4762 [M-pyridine]+,
1192.4744 calcd for C71H66BF2GaN10O.
Compound 5. The title compound was isolated as a purple
1
microcrystalline solid in 97% yield (54.0 mg, 35.8 μmol). H NMR
(300 MHz, pyridine-d5) δ (ppm): 1.04 (t, 6H, J = 7.2 Hz, CH3), 1.24
(s, 6H, CH3), 2.11 (s, 12H, CH3), 2.56 (m, 10H, CH2, CH3), 3.65 (s,
6H, OCH3), 5.25 (d, 2H, J = 5.1 Hz, CH2N), 6.04 (s, 2H, CH2), 6.91
(d, 2H, J = 8.7 Hz, HPh), 7.37 (m, 6H, Hmes, HPh), 7.50 (m, 3H, Halkene
,
Htriazole), 7.71 (m, 6H, HPh), 8.19 (d, 2H, J = 8.1 Hz, HPh), 8.29 (d, 2H,
J = 16.5 Hz, Halkene), 8.47 (d, 2H, J = 8.1 Hz, HPh), 8.76 (m, 4H, Hβ),
8.86 (d, 2H, J = 4.5 Hz, Hβ), 9.23 (d, 2H, J = 3.9 Hz, Hβ), 10.08 (m,
1H, NH). UV−vis (2-MeTHF): λmax (nm) (ε × 10−3 L mol−1 cm−1) =
368 (83), 419 (164), 605 (58), 654 (96). MS (MALDI-TOF) m/z =
1428.46 [M-pyridine]·+, 1428.56 calcd for C87H78BF2GaN10O3. HR-
MS (ESI) m/z = 1428.5610 [M-pyridine]+, 1428.5583 calcd for
C87H78BF2GaN10O3.
Compound 8. The title compound was isolated as a purple
microcrystalline solid in 97% yield (84 mg, 35.8 μmol). 1H NMR (300
MHz, pyridine-d5) δ (ppm): 1.09 (m, 6H, CH3), 1.29 (2s, 6H, CH3),
2.13 (s, 24H, CH3), 2.61 (m, 16H, CH2, CH3), 3.94 (s, 3H, OCH3),
5.48 (s, 4H, CH2), 6.07 (s, 4H, CH2), 7.29 (m, 4H, HPh), 7.37 (m, 8H,
Compound 7. BODIPY ester18 (1.10 g, 2.51 mmol) and 4-(prop-2-
yn-1-yloxy)benzaldehyde (442 mg, 2.76 mmol) were dissolved in a
mixture of dry toluene (50 mL), p-toluenesulfonic acid (PTSA, 53.0
mg, 0.308 mmol), and piperidine (3.3 mL, 33 mmol). The mixture was
3394
dx.doi.org/10.1021/ic402798f | Inorg. Chem. 2014, 53, 3392−3403